↓ Skip to main content

Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients

Overview of attention for article published in Journal of Immune Based Therapies and Vaccines, January 2011
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)

Mentioned by

news
1 news outlet
blogs
2 blogs
twitter
10 tweeters
facebook
3 Facebook pages
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
45 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients
Published in
Journal of Immune Based Therapies and Vaccines, January 2011
DOI 10.1186/1476-8518-9-7
Pubmed ID
Authors

Pedro C Rodriguez, Elia Neninger, Beatriz García, Xitlally Popa, Carmen Viada, Patricia Luaces, Gisela González, Agustin Lage, Enrique Montero, Tania Crombet

Abstract

The prognosis of patients with advanced non small cell lung (NSCLC) cancer remains dismal. Epidermal Growth Factor Receptor is over-expressed in many epithelial derived tumors and its role in the development and progression of NSCLC is widely documented. CimaVax-EGF is a therapeutic cancer vaccine composed by human recombinant Epidermal Growth Factor (EGF) conjugated to a carrier protein, P64K from Neisseria Meningitides. The vaccine is intended to induce antibodies against self EGF that would block EGF-EGFR interaction. CimaVax-EGF has been evaluated so far in more than 1000 advanced NSCLC patients, as second line therapy. Two separate studies were compared to assess the impact of high dose vaccination at multiple anatomic sites in terms of immunogenicity, safety and preliminary efficacy in stage IIIb/IV NSCLC patients. In both clinical trials, patients started vaccination 1 month after finishing first line chemotherapy. Vaccination at 4 sites with 2.4 mg of EGF (high dose) was very safe. The most frequent adverse events were grade 1 or 2 injection site reactions, fever, headache and vomiting. Patients had a trend toward higher antibody response. The percent of very good responders significantly augmented and there was a faster decrease of circulating EGF. All vaccinated patients and those classified as good responders immunized with high dose at 4 sites, had a large tendency to improved survival.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Canada 1 2%
Unknown 43 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 9 20%
Student > Bachelor 9 20%
Student > Master 6 13%
Other 3 7%
Professor > Associate Professor 3 7%
Other 7 16%
Unknown 8 18%
Readers by discipline Count As %
Medicine and Dentistry 13 29%
Agricultural and Biological Sciences 8 18%
Chemistry 4 9%
Biochemistry, Genetics and Molecular Biology 3 7%
Engineering 2 4%
Other 8 18%
Unknown 7 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 41. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 November 2020.
All research outputs
#602,102
of 17,043,172 outputs
Outputs from Journal of Immune Based Therapies and Vaccines
#1
of 28 outputs
Outputs of similar age
#4,870
of 219,107 outputs
Outputs of similar age from Journal of Immune Based Therapies and Vaccines
#1
of 1 outputs
Altmetric has tracked 17,043,172 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 28 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one scored the same or higher as 27 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 219,107 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them